Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.
Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.
Abilify sNDA For Major Depressive Disorder Gets Priority Review
Bristol/Otsuka are seeking a broader indication for the atypical antipsychotic for MDD as adjunctive to antidepressant therapy.